Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epirubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | THRB | P10828 | 8/20 | 1.00 |
| ▸ | BLM | P54132 | 8/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | STAT6 | P42226 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epirubicin SCHEMBL12349863 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL1501770 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21184881 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL14227487 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL24421866 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL14562311 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL23365786 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL22403027 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21914951 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL22291815 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7864129-B2 | Radio frequency medical treatment device and system and usage method thereof | NAMIKI SEIMITSU HOUSEKI KABUSHIKI KAISHA (JP) | 2011-01-04 | — | — | US | claimed |
| US-20230265123-A1 | PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT | PEPTINOVO BIOPHARMA INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265123-A1 | PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT | PEPTINOVO BIOPHARMA INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2022035818-A2 | PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT | PEPTINOVO BIOPHARMA, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| EP-3319980-B1 | FORMULATIONS FOR IMPROVING THE EFFICACY OF HYDROPHOBIC DRUGS | PEPTINOVO BIOPHARMA LLC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-10442890-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | VANDERBILT UNIVERSITY (US) | 2019-10-15 | — | — | US | disclosed |
| US-10328159-B2 | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds | ENGENIC MOLECULAR DELIVERY PTY LTD. (AU) | 2019-06-25 | — | — | US | disclosed |
| US-20180142061-A1 | Multifunctional Degradable Nanoparticles with Control over Size and Functionalities | UNIV VANDERBILT (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180142061-A1 | Multifunctional Degradable Nanoparticles with Control over Size and Functionalities | UNIV VANDERBILT (US) | 2018-05-24 | — | — | US | disclosed |
| US-9931408-B2 | Bio-orthogonal drug activation | KONINKLIJKE PHILIPS N.V. (NL) | 2018-04-03 | — | — | US | disclosed |
| US-20100215648-A1 | Detecting Agent and Therapeutic Agent for Highly Malignant Breast Cancer | JCL BIOASSAY CORPORATION (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100215648-A1 | Detecting Agent and Therapeutic Agent for Highly Malignant Breast Cancer | JCL BIOASSAY CORPORATION (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2205242-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | Genentech, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090306335-A1 | MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES | NATIONAL SCIENCE FOUNDATION | 2009-12-10 | — | — | US | disclosed |
| WO-2009036082-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090047221-A1 | COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF NEOPLASIA | NIPRI LIMITED (GB) | 2009-02-19 | — | — | US | disclosed |
| EP-1945265-A1 | ANTIPROLIFERATIVE COMBINATION COMPRISING CYC-682 AND A CYTOTOXIC AGENT | Cyclacel Limited (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007054731-A1 | ANTIPROLIFERATIVE COMBINATION COMPRISING CYC-682 AND A CYTOTOXIC AGENT | CYCLACEL LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| EP-1712238-A1 | Anthracyclin induced immunogenic dead or dying cells composition | INSTITUT GUSTAVE ROUSSY (FR) | 2006-10-18 | — | — | EP | disclosed |
| US-20060223812-A1 | Treating neurodegenerative conditions | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNGDER WISSENSCHAFTEN, E.V. (DE) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442890-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | DSTN, PARN, CTSA | TOP2A 2013/4885MEN1 1242/4885KMT2A 3937/4885 |
| US-20060223812-A1 | Treating neurodegenerative conditions | MAPT, HTT, PSEN2 | TOP2A 3596/4885MEN1 4383/4885KMT2A 4108/4885 |
| US-20180142061-A1 | Multifunctional Degradable Nanoparticles with Control over Size and Functionalities | DSTN, PARN, CTSA | TOP2A 2013/4885MEN1 1242/4885KMT2A 3937/4885 |
| US-20230265123-A1 | PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT | PHOSPHO1, NGLY1, ANXA11 | TOP2A 3165/4885MEN1 226/4885KMT2A 4417/4885 |
| US-20100215648-A1 | Detecting Agent and Therapeutic Agent for Highly Malignant Breast Cancer | BRCA1, CA14, CA11 | TOP2A 482/4885MEN1 1422/4885KMT2A 729/4885 |
| US-20090047221-A1 | COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF NEOPLASIA | MKI67, TP53, CCNA1 | TOP2A 32/4885MEN1 110/4885KMT2A 2604/4885 |
| US-10328159-B2 | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds | EXOSC10, EXOSC5, EXOSC4 | TOP2A 808/4885MEN1 2457/4885KMT2A 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.